Lengo Therapeutics, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2020 | $18 M | No. 1 | $10 to $50 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Lengo Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2021).
SEC Form D · Apr 2021
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Apr 2021
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Lengo Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Anna Chen | Treasurer and Secretary | Apr 2021 |
| Daniel Estes, Ph.D. | President | Apr 2021 |
| Helen Jenkins | Chief Executive Officer | Apr 2021 |
| Steve Bailey | Vice President | Apr 2021 |
| Tracy Saxton, Ph.D. | Chief Executive Officer | Apr 2020 |
| Daniel Estes, Ph.D. | President | Apr 2021 |
| David Johnson | Director | Apr 2021 |
| Helen Jenkins | Chief Executive Officer | Apr 2021 |
| Roger Ulrich, Ph.D. | Director | Apr 2021 |
| Tracy Saxton, Ph.D. | Director | Apr 2021 |